Eyecarrot Innovations Corp (TSX-V: EYC, OTCQB: EYCCF) is pleased to announce that the United States Patent and Trademark Office has issued US Patent 9,504,380 to the company covering a system and method for assessing human visual processing. This proprietary technology allows for the accurate measurement of the degree and speed of vergence facility, as well as other important measurements of human visual processing performance. With visual processing issues affecting almost 1 in 4 people globally, demand for quick and easy testing is of greater importance than ever before.
“Building out our IP portfolio and adding further protection to the BinoviTM Platform is an ongoing process. To have patented testing in place for identification of issues related to potential concussions/brain injuries, misdiagnosis of ADHD, and all general binocular vision disorders is a substantial milestone for the company. Expanding and integrating this screening data will help impact both scalability and revenue as it represents significant time savings and efficacy to the end user.” – CEO Adam Cegielski.
BinoviTM is positioned to be the global leader in how we develop the skills associated with human visual processing. Baseline testing/screening through easy to use technology and apps will allow the company to address a problem that effects hundreds of millions of people. Quick and easy screening will significantly complement what has already been developed with the BinoviTM platform. BinoviTM Screening is currently in private beta as testing continues, and the company expects its’ release in 2019.
An accurate, well-functioning and responsive vergence system is important in almost every aspect of human life, since over 40% of the brain’s neurons are used in visual processing. In order to view visual stimulus accurately a person must use their accommodative system, which changes the shape of the lens in the eye to focus the image on the retina, and the vergence system, which is the system responsible for moving the eyes so that they are properly aimed at the object being viewed. Although both the accommodative and vergence systems are used to view an object, current testing does not isolate or stress the vergence system sufficiently.
“Speed of stereopsis and vergence facility are very likely two of the most sensitive metrics to oculomotor dysfunction. Combining the two may well represent an excellent combination of speed and high sensitivity / specificity in the detection of visual dysfunction cases requiring rehabilitative intervention. This is not only the case in concussion cases or visual enhancement strategies in sports, but also in paediatric reading difficulty cases as shown in our research1“. – Dr. Patrick Quaid, PhD.
Eyecarrot’s proprietary screening technology will form an integral part of the BinoviTM platform, which enables a world-class patient experience by seamlessly combining software, hardware, data, and expert knowledge of vision care professionals. Using the BinoviTM platform, professionals are able to record and track vision performance issues, such as vergence insufficiency, and provide patients with the ultimate in expert video-guided instruction for vision-led motor activities that exercise and enhance the human visual processing system.
With over 4000 existing customers globally, Eyecarrot is excited to bring modern technology advancements to these current and new customers via the Binovi™ platform.